Clinical Trials Logo
  1. Home
  2. Condylomata Acuminata
  3. NCT01483794
  4. Details
NCT01483794 Clinical Trial

Epidemiology, Costs and Psychosocial Consequences of Genital Warts in Valparaiso, Chile

Condylomata Acuminata Clinical Trial

Official title:
Genital Warts: Studies for Establishing Epidemiological Profile, Psychosocial Consequences and Costs of Disease in Attendants to the Sexual Health Clinic of the Public Health Service of Valparaiso and San Antonio, Chile.

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT01483794
Other study ID # CondValpo2011
Secondary ID 1501
Status Not yet recruiting
Phase N/A
First received November 23, 2011
Last updated November 30, 2011
Start date November 2011
Est. completion date April 2012

Study information
Verified date November 2011
Source Universidad de Valparaiso
Contact Heraldo S Povea, MD
Phone +56-9-91629388
Email heraldopoveapacci@gmail.com
Is FDA regulated No
Health authority Chile: Ministry of Health
Study type Observational

Clinical Trial Summary

This is an observational study looking at the characteristics of patients consulting for genital warts in the first semester 2010 at the public sexual health clinic of Valparaiso, Chile. The objectives are: to have an epidemiological profile, estimating cost of the disease for the health system and the patient and analyzing possible psychosocial consequences of the condition for the patients.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 60
Est. completion date April 2012
Est. primary completion date March 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Men and women 18 years of age or older

- Having being diagnosed with genital warts

- Consulting the sexual health clinic only for genital warts

- Patients accepting to be included in the study

Exclusion Criteria:

- Immunodeficiency

- HIV positive

- Having being diagnosed with cancer or pre-cancerous lesions

- Pregnancy

- Presenting a sexual transmissible infection other than genital warts.

Study Design

Time Perspective: Retrospective

Related Conditions & MeSH terms

Locations
Country Name City State
Chile Sexual Health Clinic Valparaiso Quinta Region
Chile Sexual Health Clinic, Valparaiso Quinta Region

Sponsors (1)
Lead Sponsor Collaborator
Universidad de Valparaiso

Country where clinical trial is conducted

Chile, 

Outcome
Type Measure Description Time frame Safety issue
Primary Number of Participants with altered psychosocial tests as a Measure of impact of presenting genital warts. The psychosocial consequences of presenting genital warts will be assessed. one year No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Completed NCT00090285 - An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) Phase 3
Completed NCT00973856 - Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands N/A
Completed NCT02015260 - A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts Phase 2
Active, not recruiting NCT05056402 - An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old Phase 3
Withdrawn NCT00365443 - Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003) Phase 2
Completed NCT03935204 - Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 2
Completed NCT02405520 - Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine Phase 1
Active, not recruiting NCT02710851 - Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine Phase 2
Completed NCT04782895 - Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age Phase 3
Completed NCT03546842 - Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) Phase 3
Completed NCT03981822 - A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts Phase 2
Recruiting NCT03158480 - Safety and Efficacy of Immune Therapy for Condyloma N/A
Completed NCT01598779 - Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population N/A
Not yet recruiting NCT06430190 - Peginterferon α-2b Combined CO2 Laser in Condylomata Acuminata N/A
Completed NCT00449982 - Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts Phase 3
Completed NCT03813940 - Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 1
Not yet recruiting NCT06197802 - Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women
Completed NCT01532102 - Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts Phase 1/Phase 2
Active, not recruiting NCT06297187 - Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study